| Date Filed | Type | Description |
| 06/16/2023 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities: |
| 06/16/2023 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 06/16/2023 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 06/16/2023 |
POSASR
| Form POSASR - Post-effective Amendment to an automatic shelf registration statement: |
| 06/16/2023 |
8-K
| Resignation/termination of a director |
| 05/23/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 05/23/2023 |
8-K
| Other Events Interactive Data |
| 05/09/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/09/2023 |
8-K
| Quarterly results|
Docs:
|
"Prometheus Biosciences Reports First Quarter 2023 Financial Results and Highlights Recent Corporate Progress - Entered into agreement to be acquired by Merck; transaction expected to close in 3Q 2023 - SAN DIEGO, May 9, 2023 -- Prometheus Biosciences, Inc. , a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutics for the treatment of immune-mediated diseases, today reported financial results for the quarter ended March 31, 2023. Prometheus to be Acquired by Merck On April 15, 2023, Merck and Prometheus Biosciences entered into a definitive agreement under which Merck, through a subsidiary, has agreed to acquire Prometheus for $200.00 per share in cash for a total equity value of approximatel..." |
|
| 04/28/2023 |
PREM14A
| Form PREM14A - Preliminary proxy statements relating to merger or acquisition: |
| 04/28/2023 |
10-K/A
| Annual Report for the period ended December 31, 2022 [amend] |
| 04/17/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/17/2023 |
8-K
| Quarterly results |
| 03/08/2023 |
SC 13G/A
| Cedars Sinai Intellectual Property Co reports a 8.4% stake in Prometheus Biosciences, Inc. |
| 03/08/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 02/28/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 02/28/2023 |
8-K
| Quarterly results |
| 02/14/2023 |
SC 13G/A
| Cormorant Asset Management, LP reports a 4.5% stake in Prometheus Biosciences, Inc. |
| 02/14/2023 |
SC 13G/A
| PERCEPTIVE ADVISORS LLC reports a 2.6% stake in Prometheus Biosciences, Inc. |
| 02/14/2023 |
SC 13G/A
| EVENTIDE ASSET MANAGEMENT, LLC reports a 2.2% stake in Prometheus Biosciences, Inc. |
| 02/14/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/03/2023 |
SC 13G
| BlackRock Inc. reports a 6.1% stake in PROMETHEUS BIOSCIENCES, INC. |
| 12/09/2022 |
8-K
| Quarterly results |
| 12/09/2022 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 12/07/2022 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 12/07/2022 |
8-K
| Quarterly results |
| 11/09/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/09/2022 |
8-K
| Quarterly results |
| 10/03/2022 |
8-K
| Other Events Interactive Data |
| 08/11/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 08/11/2022 |
8-K
| Quarterly results |
| 07/26/2022 |
8-K
| Quarterly results |
| 06/08/2022 |
8-K
| Quarterly results |
| 06/06/2022 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
|